SECsense Logo

Compugen Ltd. Report: January 2025 Form 6-K on Phase 1 Clinical Trial Announcement

$CGEN
Form 6-K
Filed on: 2025-01-08
Source
Compugen Ltd. Report: January 2025 Form 6-K on Phase 1 Clinical Trial Announcement

Here's the key information extracted from the financial report (Form 6-K) filed by Compugen Ltd. for January 2025:

  1. Company Information:
  • Name: Compugen Ltd.
  • Address: 26 Harokmim Street, Holon 5885849, Israel.
  1. Filing Type:
  • This document is a Form 6-K, which is used by foreign private issuers to report on a variety of events.
  1. Filing Date:
  • The report is dated January 8, 2025.
  1. Commission File Number:
  • 000-30902.
  1. Press Release:
  • On January 8, 2025, Compugen Ltd. issued a press release announcing the first patient dosed in a Phase 1 clinical trial evaluating COM503 as a monotherapy and in combination with Zimberelimab for advanced solid tumors.
  • The press release is included as Exhibit 99.1 and is incorporated by reference into the report.
  1. Registration Statement Reference:
  • The information provided in this report is incorporated by reference into the Company’s Registration Statement on Form F-3, File No. 333-270985.
  1. Signatory:
  • The report is signed by Eran Ben Dor, General Counsel, on behalf of Compugen Ltd.

Insights:

  • The announcement regarding the clinical trial suggests that Compugen is actively progressing in its drug development pipeline, which may have implications for its future revenue potential and market position.
  • Investors and analysts may want to monitor the outcomes of this clinical trial closely, as successful results could significantly affect the company's valuation and strategic direction.
  • By filing this report and integrating the press release into its official filings, Compugen is maintaining transparency with investors and adhering to regulatory requirements, which is crucial for investor confidence.